[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Geneva, Switzerland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":300},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,73,119,155,195,223,247,269],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100413909","phase-4-antibiotics-as-adjuncts-to-periodontal-therapypharmacokinetic-considerations-and-dosing-strategies-100413909",false,"NCT04669717","Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies","Pharmacokinetic Considerations and Dosing Strategies of Amoxicillin and Metronidazole or Azithromycin as Adjunct to Non-surgical Periodontal Therapy. A Randomized,6-month, Parallel-group, Clinical Trial.","AMA","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Aged 18-80 years old with need of periodontal treatment associated with adjunctive antibiotic therapy\n* Presence of at least 30% of the teeth in the mouth with PD\\>6mm and BOP\n\nExclusion Criteria:\n\n* Persons with systemic illnesses (uncontrolled diabetes mellitus, cancer, human immunodeficiency virus, bone metabolic diseases or disorders that compromise wound healing, radiation, or immunosuppressive therapy)\n* Pregnancy or lactation\n* Persons who had taken AB within the previous 2 months\n* Persons who are taking nonsteroidal anti-inflammatory drugs\n* Persons who have a confirmed or suspected intolerance to 5-nitroimidazole derivatives or amoxicillin or macrolides\n* Previous periodontal therapy the last 1 year\n* Known or suspected non-compliance, drug or alcohol abuse\n* Inability to follow due to language problems, psychological disorders, dementia, etc. of the participant\n* Participants not willing to attend regular dental maintenance visits and follow-up evaluations\n* Participation in another study with investigational drug within the 30 days preceding and during the present study",true,"ALL","18 Years","80 Years",{"count":22,"type":23},45,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Periodontitits is a bacteria induced inflammatory disease that destroys the supporting tissues of the tooth and leads to tooth loss. Treatment consists mainly of the mechanical cleaning of the tooth surfaces in order to remove the bacterial deposits (plaque and calculus). This procedure can reduce the level of pathogenic bacteria but it can not eradicate them. In severe cases, for the complete resolution of the disease, the elimantion of certain species of bacteria is needed. In order to achieve that, the combination of different regimens of antibiotics adjunctive to the mechanical treatment has been proposed. However, dosage and duration of antimicrobial therapy should be optimal and not excessive as issues may arise related to increased antimicrobial resistance in the population and the individual due to habitual prescription of wide-spectrum antibiotic regimens, horizontal gene transfer and genetic mutation.\n\nIn the present study, in an effort to optimize the dosage and duration of the antimicrobial regimen, we will determine the pharmacokinetics (PK) and pharmacodynamic (PD) properties of the MET-AMO combination and of AZI in Gingival Crevicular Fluid (GCF), saliva and serum in severe periodontitis patients during and after either a 3-day or a 7-day course of treatment.",[29,30,31],"Periodontal Diseases","Antibiotics","Pharmacokinetics","RECRUITING","2026-04-28",{"date":35,"type":36},"2026-04-29","ACTUAL",{"date":38,"type":36},"2021-09-01",{"date":40,"type":23},"2028-12-01",{"name":42,"class":43},"University of Geneva, Switzerland","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100628441","phase-3-effects-of-neoadjuvant-immunotherapy-on-anti-tumour-immunity-in-hepatocellular-carcinoma-patients-undergoing-liver-resection-100628441","NCT07461675","Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection","Inclusion Criteria:\n\n* All adult patients undergoing liver resection for HCC at the Geneva University Hospitals (HUG), with prior informed and signed consent.\n* Patients of childbearing age must be willing to use a contraception at the day of inclusion and for at least 5 months after the last infusion.\n* Negative pregnancy test at inclusion\n* Patients will require to be eligible for surgical resection according to the BCLC guidelines (very early to early stage with preserved liver function and good patient condition) (4).\n* The control group will include data from the patients in our ongoing research project (study protocol 2023-02372), undergoing liver resection without prior ICI therapy (n = 30).\n\nExclusion Criteria:\n\n* Patients who do not ultimately undergo liver resection due to unforeseen reasons (this happens rarely, such as in the presence of unexpected HCC progression discovered during surgery).\n* Patients with an ongoing pregnancy (an unlikely event, as non-surgical HCC treatments would be prioritized in such cases).\n* Patients unable to follow procedures due to language barriers, insufficient comprehension of project language, or unable to give consent.\n* Patients \\\u003C18 years.\n* Patients with medical history of allergy or severe AEs to ICI therapy\n* Pregnant and\u002For breastfeeding women. Lactating women should stop lactation or will be excluded from the study as breastfeeding under atezolizumab is not recommended. Furthermore, breastfeeding is not recommended for at least 5 months after the last dose.\n* Immunosuppressed patients and patients with haematological disorder leading to a deficient immunity\n* Patients with hepatic and\u002For cardiovascular deficiencies that contra-indicate surgery. Compensated cirrhotic patients are expected and will be included in the study as no dosage modification of the atezolizumab is required for these patients.\n* Patients who received a live or attenuated vaccine in the last 28 days before inclusion in the study.\n* Patients with untreated Hepatitis B and\u002For C or HIV. HIV patients under treatment with normal CD4 counts can be included. Hepatitis B and\u002For C patients under antiviral therapies can be included.\n* Patients with history of inflammatory pneumopathy, active brain metastasis and patients treated with a systemic immunotherapy in the last 6 months.\n* Patients under steroid treatment during the inclusion will be excluded.",{"count":52,"type":23},30,[54],"PHASE3","Our study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor.\n\nHCC is the most prevalent primary liver cancer, responsible for nearly 800,000 deaths annually, making it the third leading cause of cancer-related mortality worldwide. Ablation by radiologic micro-waves or surgical resection represent at the moment the only curative therapies for early stages of the disease. Despite these curative options, HCC recurrence is frequent.\n\nRecently, immunotherapy has demonstrated good results on patient overall survival for advanced stages of HCC in comparison to sorafenib. Because of the beneficial effect of immunotherapy on HCC, several groups have attempt to use it as adjuvant therapy in order to reduce the recurrence rate. However the results are at the moment controversial. One can hypothetize that postoperative inflammation and liver regeneration can negatively impact the effect of the immunotherapy. Therefore, the administration of the treatmeent before surgical resection could overcome this issue.",[57,58],"Hepato Cellular Carcinoma (HCC)","Immunotherapy",[60,61,62,63],"Neoadjuvant treatment","Hepatocellular carcinoma","atezolizumab","hepatectomy","NOT_YET_RECRUITING","2026-03-04",{"date":67,"type":36},"2026-03-10",{"date":69,"type":23},"2026-03-25",{"date":71,"type":23},"2029-12-31",{"name":42,"class":43},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":18,"minAge":81,"maxAge":19,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":95,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100478607","pharmacogenomic-association-study-in-indian-children-with-acute-lymphoblastic-leukemia-100478607","NCT05512169","Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia","Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL)","MPGx-INDALL","Inclusion Criteria:\n\n* Age \\> 1 year old and ≤18 years old at enrolment\n* Previously untreated\n* ALL diagnosis confirmed by morphology and flow-cytometry\n* Indian origins\n* Fulfilling IciCle treatment protocol inclusion criteria and receiving treatment as per the protocol\n* Written Informed consent to participate in the study has to be signed by the participant\u002Fparent\u002Fguardian\n\nExclusion Criteria:\n\n* Previously tretaed patients\n* Patients with Down's syndrome\n* Patients with mature B-ALL","1 Year",{"count":83,"type":23},556,"OBSERVATIONAL","A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva.\n\nThe study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.",[87,88,89,90,91,92,93,94],"ALL, Childhood","Pediatric Cancer","Toxicity, Drug","Adverse Drug Event","Relapse Leukemia","Drug Toxicity","Drug Effect","Drug Interaction",[96,97,98,99,100,101,102,103,104,105,106,107,108,109],"Pharmacogenetics","Pharmacogenomics","Genetic polymorphism","Sequencing","Genotyping","Indian","Pediatrics","SNP","gene variant","germline genetic variant","somatic variant","biomarker","steroid response","genetic predisposition","2026-01-13",{"date":112,"type":36},"2026-01-15",{"date":114,"type":36},"2022-12-01",{"date":116,"type":23},"2027-03-30",{"name":42,"class":43},2,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":17,"sex":18,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":130,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":44},"100598503","promoting-mental-and-cognitive-health-in-old-age-through-scalable-evidence-based-interventions-100598503","NCT07072338","Promoting Mental and Cognitive Health in Old Age Through Scalable Evidence-based Interventions","PROMISE: Promoting Mental and Cognitive Health in Old Age Through Scalable Evidence-Based Interventions - Study Protocol for a Randomized Controlled Trial","PROMISE","Inclusion Criteria:\n\n* Aged 65 years or older.\n* Ability to speak and read the official language of their place of residence (French or German).\n* Ability to use and access a digital device for a digital training platform provided for the training.\n\nExclusion Criteria:\n\n* Aged below 65.\n* Inability to use and lack of access to a digital device required for using the digital training platform.","65 Years",{"count":129,"type":23},1000,[131],"NA","Mental and cognitive health are key determinants of healthy and successful aging. These two domains are closely intertwined: while chronic stress can impair cognitive functioning, cognitive decline may in turn heighten stress and reduce overall well-being in older adults. This project aims to evaluate the effectiveness and scalability of a multidomain intervention to support mental and cognitive health in older adults. A single-blind, randomized, controlled 2×2 factorial trial will be conducted with a large sample of community-dwelling adults aged 65 years and older in the German- and French-speaking regions of Switzerland. Participants will be randomly assigned to one of four intervention arms: (1) WHO Self-Help Plus stress management training (SH+), (2) multidomain cognitive training focused on lifestyle and behavior change (COG), (3) a combined SH+ and COG intervention (SH+\u002FCOG), or (4) an active control group (CG) involving podcast listening and discussion. All interventions will include in-person group sessions, while the SH+, COG, and SH+\u002FCOG arms additionally offer a digital platform for self-guided home training. Primary outcomes (mental and cognitive health), secondary outcomes and moderators (cognitive functioning, stigma, self-efficacy, self-concept, loneliness, digital literacy, cognitive reserve, sociodemographic variables) will be assessed at baseline, post-intervention (10 weeks), and at 2- and 6-month follow-ups through a self-administered ambulatory assessment.",[134,135,136],"Well-Being, Psychological","Cognition","Ageing",[138,139,140,141,142,143,144,145,146],"well-being","mental health","cognitive health","healthy aging","cognitive function","stress-management training","Acceptance and commitment therapy","cognitive training","lifrstyle intervention","2025-07-15",{"date":149,"type":36},"2025-07-18",{"date":151,"type":23},"2026-01-01",{"date":153,"type":23},"2028-06-30",{"name":42,"class":43},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":165,"briefSummary":166,"conditions":167,"keywords":175,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":44},"100595747","supporting-patients-starting-new-medicines-evaluating-the-mycare-start-service-in-switzerland-100595747","NCT07036471","Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland","Evaluation of the myCare Start Service to Support Patients Starting a New Medicine in Switzerland: A Hybrid Type II Effectiveness-implementation Study","myCare Start-I","Patients\n\nInclusion Criteria:\n\n* Must have mandatory basic health insurance in Switzerland\n* Must have been newly prescribed one or more new long-term medications in accordance with the following chronic conditions: cadisovascular diseases (incl. hyertension and thromboprophylaxis), diabetes, hyperlipidemia, depression, respiratory illness (asthma and COPD)\n* Must be able to self-manage treatment (i.e. they live at home without any support to manage their medication, exception: patient uses a pill dispenser and fills it in by him-\u002Fherself)\n* Must be able to understand language spoken by pharmacy staff and can read and understand study documents (French, German, English)\n* Must understand and are willing to consent to the myCare Start-I study (including the agreement on self-reported questionnaires and collection of health care data via their health insurance company)\n* in the intervention arm, patients must receive the myCare Start service\n\nFor this study, a new medication is a medication that has not been previously dispensed to the patient. This includes one or more new medications for a new diagnosis and or new medications for pre-existing diagnosis of a long-term condition. Included in this working definition:\n\n* The new medication is indicated for one of the five long-term diseases listed above\n* Patient has never had this active ingredient dispensed before (patient still considered eligible if they have received a small initial sample pack from their physician) or restarts an active ingredient after a period of interruption of at least 12 months (time period to be reported by the patient). Please note that for patients, that have already started a sample pack of medication the myCare Start Consultation One can start upon first dispensation at the pharmacy, there is no need to wait 7-14 days.\n* The new active ingredient can be part of a combo preparation (e.g. a diuretic added to an ACE inhibitor into the same preparation)\n* Patient has had no change in active ingredient but has an important change in treatment administration, such as:\n\n  * Change of galenic form (e.g. two different types of inhalators for asthma\u002FCOPD)\n  * Intensification of dosage regiment (e.g. twice a day instead of once a day)\n* The following change is not considered as medication initiation:\n\n  * New dosage of already known active ingredient (e.g. dose escalation of antidepressants)\n  * Simplification of administration mode (e.g. metformin 1000 mg 1-0-0 instead of 500 mg 1-0-1; change in antihypertensive drug regiment in elderly patients having vertigo in the morning: 0-0-X instead of X-0-0)\n\nExclusion Criteria:\n\n* Patients participating or having participated in an education program about their disease or treatment in the last 3 months, led by healthcare providers such as physicians, nurses, pharmacists or other (e.g. education provided by nurses for type I diabetes patients)\n\nPhysicians:\n\nInclusion criteria\n\n\\- Any physician treating a patient for one of the five long-term illnesses listed above is eligible to refer the patient to a pharmacy providing myCare start.\n\nPharmacies:\n\nInclusion criteria:\n\n* Have to be enrolled into the myCare Start service and comply to the requirements of the pharmacy quality system management of having access to a private consultation room or area\n* Must agree to participate in the research study, including the recruitment of control patients and the delivery of the myCare Start service to intervention patients.",{"count":164,"type":23},1600,[131],"In Phase B, the aim is to evaluate the myCare Start service in routine care within the ambulatory primary care medicine and community pharmacy setting in Switzerland. A Type II hybrid effectiveness-implementation study will be conducted to evaluate the effectiveness (improvement in adherence), cost-effectiveness and implementation of the service. This evaluation will allow us to build the necessary contextual relevant evidence base to support sustainable funding of the service in the long term.",[168,169,170,171,172,173,174],"Cardio-vascular Disease","Depression Disorders","Diabetes","COPD","Asthma Bronchiale","Hyperlipidaemia","Medication Initiation for Long-term Conditions",[176,177,178,179,180,181,182,183,184,185,186],"patient adherence","medication adherence","medication initiation","long-term treatment","implementation science","interprofessional collaboration","outpatient care","community pharmacy","general practitioner","cost-effectiveness","medication adherence support programme","2025-06-16",{"date":189,"type":36},"2025-06-25",{"date":191,"type":23},"2025-06",{"date":193,"type":23},"2027-01",{"name":42,"class":43},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":18,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":24,"phases":207,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100436003","the-disrupted-bodily-self-of-patients-100436003","NCT04957576","The Disrupted Bodily Self of Patients","This is Not my Body: the Disrupted Bodily Self of Neurological Patients","DISOWN","Inclusion Criteria:\n\n* First neurological event, affecting the right hemisphere or the left hemisphere (stroke);\n* Structural images of the brain lesion available (magnetic resonance or tomographic scans);\n* Full somato-sensory deficit affecting the left hand;\n* Good (or corrected) visual acuity;\n* Good proficiency in French;\n* Right-handed\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria ;\n* Presence of general cognitive deficits and\u002For suspicious of possible cognitive deficits;\n* Presence of difficulty in task's comprehension;\n* Impossibility to sustain a research session of at least 45minutes (e.g., attentional lability);\n* Precedent additional neurological disorder and\u002For current or precedent psychiatric disease.","20 Years","85 Years",{"count":206,"type":23},5,[131],"Some pathological clinical conditions can strongly perturb the link between body and self. One disorder of body representation is the feeling of disownership over body parts, experienced by neurological patients usually after a stroke affecting the right hemisphere. Body disownership and more complex somatoparaphrenic delusions are described as rare in the scientific literature and no clear consensus about their features, brain correlates and recovery mechanisms are on record. Recently, the investigators have discovered that using new sensitive tools it is possible to unveil the presence of covert disownership deficits in patients, who seemed completely unimpaired at the standard assessment. Within a bigger exploratory study of this covert disownership in stroke patients, the aim is to implement a proof-of-concept rehabilitation study, using a multisensory stimulation paradigm, with the hypothesis that a positive remission of disownership will be found and that this treatment can influence both the implicit and explicit features of disownership.",[210,211],"Stroke","Body, Foreign",[213,214,215],"Disownership","Rubber Hand Illusion","Multisensory Stimulation","2025-05-23",{"date":218,"type":36},"2025-05-30",{"date":193,"type":23},{"date":221,"type":23},"2029-12",{"name":42,"class":43},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":18,"minAge":203,"maxAge":204,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":233,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":246,"locationsCount":4},"100427401","improving-awareness-for-spatial-neglect-with-tdcs-100427401","NCT04845529","Improving Awareness for Spatial Neglect With tDCS","Improving Awareness in Right-brain-damaged Patients With Unilateral Spatial Neglect Using Transcranial Direct Current Stimulation (tDCS)","ANOSO","Inclusion Criteria:\n\n* First stroke affecting the right-hemisphere\n* Presence of USN, as assessed by a standard neuropsychological evaluation\n* Structural images of the brain lesion available (magnetic resonance or tomographic scans)\n* Criteria for electrical brain stimulation\n* Good (or corrected) visual acuity\n* High proficiency in French\n* Right-handed\n\nExclusion Criteria:\n\n* Presence of general cognitive deficits and\u002For suspicious of possible cognitive deficits\n* Presence of difficulty in task's comprehension\n* Impossibility to sustain a research session of at least 45minutes (e.g., attentional lability)\n* Precedent additional neurological disorder and\u002For current or precedent psychiatric disease\n* Presence of one or more exclusion criteria for the electrical brain stimulation 18, as following:\n\nPresence (or suspected presence) of metal in the brain or skull or body (except titanium) (e.g. splinters, fragments, clips, etc.) Presence of cochlear implants, implanted neuro-stimulator (e.g., DBS, epidural\u002Fsubdural, VNS), cardiac pacemaker, medication infusion device, spinal or ventricular derivations Presence of epilepsy (participant and\u002For the close family) and\u002For precedent epileptic seizures (participant) Presence of a fainting spell or syncope, due to neurological diseases (not consider syncope during blood sampling or after being in a warm environment or after emotionally stressful events) Presence of a severe (i.e., followed by loss of consciousness) head trauma Presence of hearing problems or ringing in your ears (e.g. tinnitus) Current treatment under psychoactive (e.g. antidepressants, tranquilizers) or antiepileptic medications Chronic headache For women: you are pregnant or there is any chance that you might be.",{"count":232,"type":23},12,[131],"Brain-damaged patients can show severe neurological and cognitive deficits, and yet often remain strikingly unaware of these symptoms: this condition is called anosognosia. The aim of this study is to improve awareness in right-brain-damaged patients with Unilateral Spatial Neglect (USN) following stroke using transcranial direct current stimulation (tDCS). tDCS is a neuromodulatory technique that delivers low-intensity current to the brain facilitating (anodal tDCS) or inhibiting (cathodal tDCS) spontaneous neuronal activity. tDCS does not induce activity in resting neuronal networks, but modulates spontaneous neuronal activity: consequently, the amount and direction of effects critically depend on the previous state of the neural structures.\n\nWe will test USN patients showing anosognosia for neglect symptoms. Different brain areas will be stimulated, to target explicit and implicit components of anosognosia, including parietal and frontal brain regions.",[210,236,237],"Anosognosia","Neglect, Hemispatial",[239,240,241],"Brain modulation","Recovery","Implicit and explicit anosognosia",{"date":218,"type":36},{"date":244,"type":23},"2026-12",{"date":193,"type":23},{"name":42,"class":43},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":24,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":44},"100522093","neglect-treatment-by-prism-adaptation-in-the-acute-phase-100522093","NCT06078111","Neglect Treatment by Prism Adaptation in the Acute Phase","aPA-NEGLECT","Inclusion Criteria:\n\n* First neurological event, affecting the right hemisphere or the left hemisphere (stroke, brain tumour post-surgery);\n* Structural images of the brain lesion available (magnetic resonance or tomographic scans);\n* Good Normal (or corrected) visual acuity;\n* Presence of USN, as assessed by a standard neuropsychological evaluation.\n\nExclusion Criteria:\n\n* Previous neurological disorder and\u002For current or previous psychiatric disease.\n* Presence or suspicion of previous general cognitive deficits documented from the clinical dossier and\u002For suspicious of possible cognitive deficits ;\n* Presence of difficulty in task's comprehension preventing its completion;\n* Impossibility to sustain a research session of at least 30 minutes (e.g., attentional lability).","90 Years",{"count":256,"type":23},32,[131],"This project aims at unveiling the beneficial effects of prism adaptation as early rehabilitation technique to treat unilateral spatial neglect in the acute phase after a brain damage. This syndrome, frequent and very invalidating for daily life activities after a brain damage, is a cognitive disorder of lack of attention towards a part of the space. Patients at a first event brain injury hospitalized into the Neurology and Neurosurgery Departments and affected by spatial neglect will undergo to a protocol of five consecutive rehabilitation treatments, being assigned to the experimental (prisms) or control groups (neutral prisms). The effectiveness of the treatment will be assessed with cognitive, functional and motor-related measures, as well as a follow up 3 months later. These results can have a strong impact on the long-term functional outcome of these patients.",[260],"Unilateral Spatial Neglect","2024-06-25",{"date":263,"type":36},"2024-06-27",{"date":265,"type":36},"2023-11-01",{"date":267,"type":23},"2026-02",{"name":42,"class":43},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":17,"sex":18,"minAge":277,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":24,"phases":280,"briefSummary":281,"conditions":282,"keywords":285,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":44},"100417293","two-unit-cantilever-implant-prostheses-made-of-monolithic-zirconia-or-pfm-100417293","NCT04713800","Two-unit Cantilever Implant Prostheses Made of Monolithic Zirconia or PFM","Randomized Controlled Clinical Trial of Two-unit Cantilever Implant Prostheses Made of Monolithic Zirconia on Titanium Base Abutments or Porcelain-fused to Metal on Gold Abutments","Cantilever","Inclusion Criteria:\n\n* Minimal age of 22 years old.\n* No general medical condition which represents a contraindication to implant treatment\n* Good oral hygiene (PII ≤ 20%), and healthy periodontal tissues (BOP≤ 20%)\n* Two adjacent-teeth gap in posterior maxilla or mandible arch (first premolar, second premolar, first molar, second molar) with an osseointegrated regular or wide-diameter bone-level implant in a prosthetically correct position to allow occlusal screw-retention. Free-end edentulous gaps can also be included\n* Presence of antagonist occlusal units\n\nExclusion Criteria:\n\n* Severe bruxism or clenching habits\n* Patients with inadequate oral hygiene or persistent intraoral infection\n* Women who are pregnant or breast feeding at the day of inclusion\n* Smokers exceeding 15 cigarettes \u002F day, or equivalent; patients chewing tobacco\n* Unable or unwilling to cooperate for the trial period\n* Estimated cantilever crown mesial-distal length \\> 10 mm\n* Estimated implant crown height (from implant platform to occlusal contact points) \\> 15 mm","22 Years",{"count":279,"type":23},38,[131],"The aim of is to compare the survival rate and technical outcomes of cantilever implant-supported fixed denture prosthetics (cFDPs) made either out of monolithic zirconia bonded to a titanium base in a digital workflow, or porcelain fused-to metal using a gold abutment in a conventional workflow. In addition, biological outcomes, wear patterns, PROMs and time efficiency will be recorded. The null hypothesis is: the reconstruction type does not influence the survival rate and technical outcomes of 2-unit implant-supported cFDP.",[283,284],"Jaw, Edentulous, Partially","Missing Teeth",[286,275,287,288,289,290,291],"Dental Implants","Titanium base","Dental abutment","Fixed dental prosthesis","Monolithic zirconia","Porcelain fused to metal","2022-11-21",{"date":294,"type":36},"2022-11-23",{"date":296,"type":36},"2021-07-28",{"date":298,"type":23},"2027-07",{"name":42,"class":43},""]